Literature DB >> 12113234

Oncolytics Biotech releases REOLYSIN phase I clinical trial results.

.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12113234

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  1 in total

1.  Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

Authors:  Jennifer L Leddon; Chun-Yu Chen; Mark A Currier; Pin-Yi Wang; Francesca A Jung; Nicholas L Denton; Kevin M Cripe; Kellie B Haworth; Michael A Arnold; Amy C Gross; Timothy D Eubank; William F Goins; Joseph C Glorioso; Justus B Cohen; Paola Grandi; David A Hildeman; Timothy P Cripe
Journal:  Mol Ther Oncolytics       Date:  2015-01-21       Impact factor: 7.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.